tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksChatGPT StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert CenterTipRanksAI
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Daily Analyst Ratings
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
ChatGPT Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

APGE Stock Latest News

Apogee Therapeutics Starts Phase 2 Trial for Atopic Dermatitis Drug
Company AnnouncementsApogee Therapeutics Starts Phase 2 Trial for Atopic Dermatitis Drug
10h ago
8K
APGE
Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
PremiumPress Releases
Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
11h ago
APGE
Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results
PremiumPress Releases
Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results
3d ago
APGE
Apogee expects cash to fund operations into Q1 of 2028
PremiumThe Fly
Apogee expects cash to fund operations into Q1 of 2028
3d ago
APGE
Warner Bros. upgraded, Cerence downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Warner Bros. upgraded, Cerence downgraded: Wall Street’s top analyst calls
6d ago
BAX
MMM
BofA sees Apogee with ‘best-in-class drug’ potential, starts with a Buy
PremiumThe FlyBofA sees Apogee with ‘best-in-class drug’ potential, starts with a Buy
6d ago
APGE
Apogee Therapeutics initiated with a Buy at BofA
PremiumThe Fly
Apogee Therapeutics initiated with a Buy at BofA
6d ago
APGE
Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference
PremiumPress Releases
Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference
10d ago
APGE
Apogee Therapeutics participates in a conference call with Jefferies
PremiumThe Fly
Apogee Therapeutics participates in a conference call with Jefferies
13d ago
APGE
Spyre Therapeutics price target raised to $54 from $36 at Stifel
PremiumThe Fly
Spyre Therapeutics price target raised to $54 from $36 at Stifel
2M ago
APGE
ATXS
Apogee Therapeutics Launches Innovative Antibody Clinical Trial
PremiumCompany Announcements
Apogee Therapeutics Launches Innovative Antibody Clinical Trial
2M ago
8K
APGE
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases
PremiumPress Releases
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases
2M ago
APGE
Apogee announces first participants dosed in Phase 1 trial of APG808
PremiumThe FlyApogee announces first participants dosed in Phase 1 trial of APG808
2M ago
APGE
Four new option listings on March 20th
PremiumThe Fly
Four new option listings on March 20th
2M ago
ADTH
APGE
Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million
PremiumPress Releases
Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million
2M ago
APGE
Apogee Therapeutics 6.77M share Secondary priced at $62.00
PremiumThe Fly
Apogee Therapeutics 6.77M share Secondary priced at $62.00
2M ago
APGE
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering
PremiumPress Releases
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering
2M ago
APGE
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
PremiumPress Releases
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
2M ago
APGE
Apogee Therapeutics announces $350M common stock offering
PremiumThe Fly
Apogee Therapeutics announces $350M common stock offering
2M ago
APGE
Apogee Therapeutics files to sell 6M shares of common stock
PremiumThe FlyApogee Therapeutics files to sell 6M shares of common stock
2M ago
APGE
Apogee Therapeutics price target raised to $95 from $46 at Stifel
PremiumThe Fly
Apogee Therapeutics price target raised to $95 from $46 at Stifel
2M ago
APGE
Apogee Therapeutics Unveils Promising APG777 Phase 1 Data
PremiumCompany Announcements
Apogee Therapeutics Unveils Promising APG777 Phase 1 Data
2M ago
8K
APGE

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >